☆ 4.7 Review

Soluble PCSK9 Inhibition: Indications, Clinical Impact, New Molecular Insights and Practical Approach-Where Do We Stand?

JOURNAL OF CLINICAL MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Cardiac & Cardiovascular Systems

Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose-Response

Fernando Scudiero et al.

Summary: This study assessed the association between body mass index (BMI) and platelet reactivity in STEMI patients treated with oral 3(rd) generation P2Y(12) inhibitors. The results showed that patients with BMI >= 25 had higher platelet reactivity at 1 and 2 hours after the loading dose of the medication, and BMI >= 25 was an independent predictor of high on-treatment platelet reactivity at 2 hours.

CARDIOVASCULAR DRUGS AND THERAPY (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials

Francesco Costa et al.

Summary: The study evaluated the impact of an abbreviated dual antiplatelet therapy (DAPT) regimen in high bleeding risk patients after percutaneous coronary intervention (PCI), using existing evidence. It found that a shorter DAPT duration (1-3 months) reduced bleeding and cardiovascular mortality without increasing ischemic events in these patients.

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Combination lipid-lowering therapy as first-line strategy in very high-risk patients

Kausik K. Ray et al.

EUROPEAN HEART JOURNAL (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Clinical outcome of patients with ST-elevation myocardial infarction and angiographic evidence of coronary artery ectasia

Cesare Baldi et al.

Summary: This study aimed to describe the prevalence of coronary artery ectasia (CAE) in patients with ST-elevation myocardial infarction (STEMI) and assess the long-term outcome. Patients with CAE had a higher risk of recurrent myocardial infarction (MI) during follow-up compared to those without CAE.

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Gene Therapy Targeting PCSK9

Julius L. Katzmann et al.

Summary: Recent developments in cardiovascular prevention research have shown successful treatments for LDL hypercholesterolemia, such as inhibiting the PCSK9 gene or using specific drugs. These methods have led to long-term reductions in LDL cholesterol levels and have the potential to fundamentally change our approach to cardiovascular prevention.

METABOLITES (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Treatment and Outcome of Patients With Coronary Artery Ectasia: Current Evidence and Novel Opportunities for an Old Dilemma

Luca Esposito et al.

Summary: Coronary artery ectasia (CAE) is a vascular disease with unclear pathophysiology, potentially associated with atherosclerosis. The prognostic role of CAE is controversial, but studies have shown a higher risk of cardiovascular events and mortality in these patients after intervention. There is no standardized approach for the treatment of CAE, as therapy needs to be tailored to the individual patient. Interventional treatment of CAE presents challenges, often complicated by complications such as thrombus embolization and stent malapposition. The optimal choice of antithrombotic therapy is still debated.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction The PACMAN-AMI Randomized Clinical Trial

Lorenz Raber et al.

Summary: Among patients with acute myocardial infarction, the addition of biweekly subcutaneous alirocumab to high-intensity statin therapy resulted in significantly greater regression of coronary plaques in non-infarct-related arteries after 52 weeks. Further research is needed to understand whether alirocumab improves clinical outcomes in this population.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis

Marianna Puccini et al.

Summary: PCSK9 affects platelet function and blood coagulation. Elevated blood PCSK9 levels are associated with increased platelet reactivity and platelet count. Additionally, PCSK9 affects crucial factors in the coagulation cascade.

METABOLITES (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Relationship between PCSK9 and endothelial function in patients with acute myocardial infarction

Paolo Cimaglia et al.

Summary: The study aimed to evaluate the relationship between PCSK9 and endothelial dysfunction in patients with acute myocardial infarction. The results showed a positive correlation between PCSK9 and apoptosis rate, and an increase in PCSK9 levels within 5 days after myocardial infarction, while apoptosis rate remained unchanged. Reduction of PCSK9 was associated with a decrease in apoptosis rate.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Michelle L. O'Donoghue et al.

Summary: Long-term use of evolocumab to lower LDL-C levels is associated with low rates of adverse events, which do not exceed those in the placebo group. Over time, the use of evolocumab also leads to further reduction in cardiovascular events.

CIRCULATION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes

Angelo Silverio et al.

Summary: This study found that elevated levels of lipoprotein(a) (Lp(a)) were significantly associated with an increased risk of recurrent myocardial infarction (MI) and all-cause death in patients with a history of MI. However, this association was only observed in non-diabetic patients and not in those with diabetes.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9

Nicola Ferri et al.

Summary: The immediate and aggressive use of lipid-lowering therapies after ACS and PCI, including anti-PCSK9 monoclonal antibodies, is currently under investigation to explore their efficacy in reducing the risk of MACE. Current evidence suggests that the inhibition of PCSK9 with evolocumab and alirocumab could have a potential clinical impact in lowering LDL-C levels in ACS patients.

PHARMACOLOGICAL RESEARCH (2022)

添加到收藏夹

Review Medicine, General & Internal

Incremental Value of Polygenic Risk Scores in Primary Prevention of Coronary Heart Disease A Review

Jacob William Groenendyk et al.

Summary: Polygenic risk scores (PRS) have shown significant association with coronary heart disease (CHD) risk in all the reviewed studies. The improvement in C statistic and net reclassification indexes when PRS was added to traditional risk scores ranged from negligible to modest. Adding PRS to traditional risk scores does not appear to provide meaningful improvements in clinical decision-making in primary prevention populations, based on established risk prediction metrics.

JAMA INTERNAL MEDICINE (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

A Comprehensive Review of PCSK9 Inhibitors

Caroline Coppinger et al.

Summary: Cardiovascular disease is a leading cause of death globally, and high levels of LDL-C are a major risk factor. PCSK9 inhibitors have been found to significantly reduce LDL-C levels and lower the occurrence of major adverse cardiovascular events in high-risk patients. They can be used in populations who are intolerant to statins or do not achieve their treatment goals.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prevalence and Predictors of Out-of-Target LDL Cholesterol 1 to 3 Years After Myocardial Infarction. A Subanalysis From the EYESHOT Post-MI Registry

Angelo Silverio et al.

Summary: In patients presenting to cardiologists 1 to 3 years after MI, a significant proportion have uncontrolled LDL-C levels, especially among those with low education levels or without hypertension. The use of LDL-C-lowering drug therapies is underutilized in this high-risk population.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients

Angelo Silverio et al.

Summary: This meta-analysis suggests that older age and diabetes are associated with a higher risk of in-hospital mortality in patients infected with SARS-CoV-2. Conversely, male sex, hypertension, and smoking did not independently correlate with fatal outcomes.

BMC CARDIOVASCULAR DISORDERS (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study

Stephen J. Nicholls et al.

Summary: The HUYGENS study aims to evaluate the impact of incremental lipid lowering using the PCSK9 inhibitor evolocumab on plaque features in ACS patients treated with statins. The study will use OCT imaging to assess the effects of evolocumab on coronary atherosclerotic plaques, with the primary endpoint being evaluated at baseline and week 50.

CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

A Critical Review of the Efficacy and Safety of Inclisiran

Jennifer Hardy et al.

Summary: The traditional statin therapy may not effectively reduce LDL-C levels in a substantial proportion of patients, leading to the exploration of new treatments like PCSK9 antibodies or RNA-based drugs. However, concerns about patient compliance have been raised with these emerging therapies.

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2021)

添加到收藏夹

Article Physiology

Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol

Jing Gao et al.

Summary: The EMSIACS study aims to investigate the impact of combining evolocumab with moderate-intensity statin therapy on LDL-C levels and incidence of MACE in Chinese ACS patients.

FRONTIERS IN PHYSIOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Pleiotropic Effects of PCSK-9 Inhibitors

Marcin Basiak et al.

Summary: PCSK-9 inhibitors are a group of drugs that reduce the degradation of LDL-R, increase the uptake of LDLc, and have various pleiotropic effects beyond lipid-lowering, including anti-atherosclerotic, anti-aggregation, anticoagulant, antineoplastic effects, and influence on bacterial infections. This review article systematically examines the current scientific data on the multifaceted effects of PCSK-9 inhibitors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Predictors of Recurrent Ischemic Events in Patients With ST-Segment Elevation Myocardial Infarction

Gennaro Galasso et al.

Summary: In patients with ST-segment elevation myocardial infarction (STEMI), diabetes, Lp(a) serum levels, and restenotic lesions were independently associated with recurrent MI at long term. A Lp(a) level >= 30 mg/dL showed an incremental risk stratification capability, especially in patients with diabetes or both diabetes and restenotic lesions.

AMERICAN JOURNAL OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Epidemiology of Peripheral Artery Disease and Polyvascular Disease

Aaron W. Aday et al.

Summary: PAD is increasingly recognized as a major cause of cardiovascular morbidity and mortality worldwide. The focus on PAD in recent years has led to new epidemiological insights and highlighted the importance of polyvascular disease in cardiovascular research and clinical practice. PAD may present similar or even greater risk compared to coronary artery disease or stroke.

CIRCULATION RESEARCH (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial

Elvin Kedhi et al.

Summary: This study aimed to investigate the impact of TCFA on clinical outcomes of DM patients with FFR-negative lesions, showing that patients with TCFA had a significantly higher risk of major adverse clinical events compared to those without TCFA.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial

Elvin Kedhi et al.

Summary: This study aimed to investigate the impact of optical coherence tomography (OCT)-detected thin-cap fibroatheroma (TCFA) on clinical outcomes of diabetes mellitus (DM) patients with fractional flow reserve (FFR)-negative lesions. The results showed that among DM patients with FFR-negative lesions, TCFA-positive patients had a five-fold higher rate of major adverse clinical events (MACE) compared to TCFA-negative patients, suggesting a potential paradigm shift for coronary artery disease risk stratification in DM patients.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

Francois Mach et al.

EUROPEAN HEART JOURNAL (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis

Peter R. Sinnaeve et al.

EUROPEAN HEART JOURNAL (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Percutaneous Treatment and Outcomes of Small Coronary Vessels A SCAAR Report

Angelo Silverio et al.

JACC-CARDIOVASCULAR INTERVENTIONS (2020)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Effect of PCSK-9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque Assessed by Near-Infrared Spectroscopy

Hiroyuki Omori et al.

JACC-CARDIOVASCULAR IMAGING (2020)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period A Placebo-Controlled, Randomized Trial

Thorsten M. Leucker et al.

CIRCULATION (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer

Xinjian Liu et al.

NATURE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Mortality From Ischemic Heart Disease Analysis of Data From the World Health Organization and Coronary Artery Disease Risk Factors From NCD Risk Factor Collaboration

Alexandra N. Nowbar et al.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

Konstantinos C. Koskinas et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K. Ray et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

添加到收藏夹

Review Hematology

PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention

Francesco Paciullo et al.

THROMBOSIS AND HAEMOSTASIS (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

Edward Lee et al.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review

Eliano P. Navarese et al.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials

Konstantinos C. Koskinas et al.

EUROPEAN HEART JOURNAL (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany

Winfried Maerz et al.

ATHEROSCLEROSIS (2018)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

PCSK9 From Basic Science Discoveries to Clinical Trials

Michael D. Shapiro et al.

CIRCULATION RESEARCH (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

Sreeneeranj Kasichayanula et al.

CLINICAL PHARMACOKINETICS (2018)

添加到收藏夹

Review Peripheral Vascular Disease

Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation

Angelos D. Karagiannis et al.

CURRENT ATHEROSCLEROSIS REPORTS (2018)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

The Evolving Future of PCSK9 Inhibitors

Robert S. Rosenson et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Marc P. Bonaca et al.

CIRCULATION (2018)

添加到收藏夹

Article Medicine, General & Internal

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

G. G. Schwartz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

John P. Gibbs et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Brian A. Ference et al.

EUROPEAN HEART JOURNAL (2017)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Alirocumab for the treatment of hypercholesterolemia

Brian Tomlinson et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials

Giuseppe De Luca et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano et al.

LANCET (2017)

添加到收藏夹

Article Medicine, General & Internal

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Marc S. Sabatine et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab

Nihar R. Desai et al.

JAMA CARDIOLOGY (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up

Antonio J. Vallejo-Vaz et al.

CIRCULATION (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway

Zhi-Han Tang et al.

ATHEROSCLEROSIS (2017)

添加到收藏夹

Article Hematology

Loss of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor- Inhibition

Lin Zhu et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

Michel Farnier et al.

ATHEROSCLEROSIS (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

Alberico L. Catapano et al.

ATHEROSCLEROSIS (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study

Leslie Cho et al.

CARDIOVASCULAR DRUGS AND THERAPY (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher

Henry N. Ginsberg et al.

CARDIOVASCULAR DRUGS AND THERAPY (2016)

添加到收藏夹

Review Medicine, General & Internal

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis

Michael G. Silverman et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Medicine, General & Internal

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial

Stephen J. Nicholls et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance The GAUSS-3 Randomized Clinical Trial

Steven E. Nissen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Very high-pressure dilatation for undilatable coronary lesions: indications and results with a new dedicated balloon

Gioel Gabrio Secco et al.

EUROINTERVENTION (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Erik Stroes et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

Dean J. Kereiakes et al.

AMERICAN HEART JOURNAL (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta

Zufeng Ding et al.

ANTIOXIDANTS & REDOX SIGNALING (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study

Lucia Barbieri et al.

ATHEROSCLEROSIS (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease

M. Verdoia et al.

DIABETES & METABOLISM (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

Christopher P. Cannon et al.

EUROPEAN HEART JOURNAL (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial

Harold Bays et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Patrick M. Moriarty et al.

JOURNAL OF CLINICAL LIPIDOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal et al.

LANCET (2015)

添加到收藏夹

Article Medicine, General & Internal

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal et al.

LANCET (2015)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Jennifer G. Robinson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Marc S. Sabatine et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks

Eli M. Roth et al.

FUTURE CARDIOLOGY (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies

John J. P. Kastelein et al.

CARDIOVASCULAR DRUGS AND THERAPY (2014)

添加到收藏夹

Article Medicine, General & Internal

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial

Jennifer G. Robinson et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management: A Meta-analysis of Randomized Trials

Monica Verdoia et al.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts

My-Anh Nguyen et al.

JOURNAL OF LIPID RESEARCH (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Erik Stroes et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Anti-PCSK9 Monotherapy for Hypercholesterolemia The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab

Michael J. Koren et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Neil J. Stone et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Dirk J. Blom et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Cell Biology

PCSK9 is a critical regulator of the innate immune response and septic shock outcome

Keith R. Walley et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

添加到收藏夹

Article Pharmacology & Pharmacy

Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering

Tracy Mitchell et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation

Hagai Tavori et al.

CIRCULATION (2013)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

A meta-analytic overview of thrombectomy during primary angioplasty

Giuseppe De Luca et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI

Giuseppe De Luca et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

Maryssa Canuel et al.

PLOS ONE (2013)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial

Frederick Raal et al.

CIRCULATION (2012)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Meta-Analysis of Randomized Trials of Glycoprotein IIb/IIIa Inhibitors in High-Risk Acute Coronary Syndromes Patients Undergoing Invasive Strategy

Giuseppe De Luca et al.

AMERICAN JOURNAL OF CARDIOLOGY (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population

Giuseppe De Luca et al.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

PCSK9 R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease 3 Independent Studies and Meta-Analyses

Marianne Benn et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

Markey C. McNutt et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2009)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Beyond established and novel risk factors - Lifestyle risk factors for cardiovascular disease

Dariush Mozaffarian et al.

CIRCULATION (2008)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: A meta-regression analysis of randomized trials

G De Luca et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

C Baigent et al.

LANCET (2005)

添加到收藏夹

Article Genetics & Heredity

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9

C Jonathan et al.

NATURE GENETICS (2005)

添加到收藏夹

Article Hematology

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

G Dubuc et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.